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Endoglin (CD105) is the target gene for the hereditary
hemorrhagic telangiectasia type I (HHT1), a dominantly
inherited vascular disorder. It shares with betaglycan a
limited amino acid sequence homology and being com-
ponents of the membrane transforming growth factor-b
(TGF-b) receptor complex. Using rat myoblasts as a
model system, we found that overexpression of endoglin
led to a decreased TGF-b response to cellular growth
inhibition and plasminogen activator inhibitor-1 syn-
thesis, whereas overexpression of betaglycan resulted
in an enhanced response to inhibition of cellular prolif-
eration and plasminogen activator inhibitor-1 induced
expression in the presence of TGF-b. The regulation by
endoglin of TGF-b responses seems to reside on the ex-
tracellular domain, as evidenced by the functional anal-
ysis of two chimeric proteins containing different com-
binations of endoglin and betaglycan domains. Binding
followed by cross-linking with 125I-TGF-b1 demon-
strated that betaglycan expressing cells displayed a
clear increase (about 3.5-fold), whereas endoglin ex-
pressing cells only displayed an slight increment (about
1.6-fold) in ligand binding with respect to mock trans-
fectants. SDS-polyacrylamide gel electrophoresis analy-
sis of radiolabeled receptors demonstrated that expres-
sion of endoglin or betaglycan is associated with an
increased TGF-b binding to the signaling receptor com-
plex; however, while endoglin increased binding to
types I and II receptors, betaglycan increased the bind-
ing to the type II receptor. Conversely, we found that
TGF-b binding to endoglin required the presence of re-
ceptor type II as evidenced by transient transfections
experiments in COS cells. These findings suggest a role
for endoglin in TGF-b responses distinct from that of
betaglycan.
Endoglin (CD105), is a 180-kDa homodimeric membrane gly-
coprotein strongly expressed by human endothelial cells (1).
The gene encoding endoglin has been identified as the target
for the dominant vascular disorder known as hereditary hem-
orrhagic telangiectasia type 1 (HHT1)1 (2, 3). HHT is a highly
penetrant autosomal dominant vascular dysplasia associated
with frequent epistaxis, gastrointestinal bleedings, telangiec-
tases, and arteriovenous malformations in brain, lung, and
liver (4, 5). The specific function of endoglin responsible for the
vascular dysplasia in HHT1 is not known, but it is likely
related to the transforming growth factor-b (TGF-b) system as
endoglin is a functional component of the membrane TGF-b
receptor complex. Endoglin binds TGF-b1 and TGF-b3 with
high affinity (KD 5 50 pM) in human endothelial cells (6); the
heteromeric association between endoglin and the TGF-b sig-
naling receptors I (R-I) and II (R-II) has been suggested by
co-immunoprecipitation experiments (7, 8), and overexpression
of endoglin is able to modulate cellular responses to TGF-b (9).
TGF-b is a member of a large family of proteins that has many
biological effects including regulation of cellular proliferation,
differentiation, migration, and extracellular matrix formation
(10, 11). Cellular responses to TGF-b also comprise the expres-
sion of genes encoding protease inhibitors such as the increased
secretion of the 45-kDa plasminogen activator inhibitor-1
(PAI-1) (12, 13). In humans, three isoforms have been identi-
fied, namely TGF-b1, TGF-b2, and TGF-b3. Thus, perturbation
of one or more of these processes may cause the vascular
dysplasia observed in HHT1 patients.
TGF-bs exert their function through binding to a large fam-
ily of specific receptors, including receptors type I, II, betagly-
can, and endoglin (14, 15). Among these, the serine-threonine
kinase receptors types I and II are necessary for all tested
biological responses to TGF-b and transmit the signal to down-
stream substrates through their kinase activity. By contrast,
endoglin and betaglycan have been postulated as regulators of
TGF-b access to the signaling receptors. Endoglin and beta-
glycan share a region of high identity in the cytoplasmic tail,
but show a limited homology on the extracellular domain (16–
19). On the other hand, endoglin and betaglycan markedly
differ in their cellular distribution, and from the functional
point of view, endoglin has been shown to inhibit TGF-b1
responses in human monocytic cells (9), whereas betaglycan
seems to increase TGF-b2 signaling, leaving unaffected the
TGF-b1 response in rat myoblasts (20). Unfortunately, these
studies were carried out in different cellular lineages and com-
parative conclusions about endoglin with respect of betaglycan
could not be drawn. Here, we have used a common cell type to
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further analyze the role of endoglin and its homologue betaglycan
in the TGF-b cellular responses, as well as the interdependence
of endoglin and the signaling receptors in ligand binding.
EXPERIMENTAL PROCEDURES
Plasmids—The pcEXV-EndoL vector containing the human L-endog-
lin isoform driven by the SV40 promoter (21) was used in transfection
experiments of rat myoblasts. The pCMV-EndoL vector, containing the
human L-endoglin isoform driven by the cytomegalovirus promoter,
was constructed by inserting the 2.3-kb EcoRI endoglin cDNA, obtained
by digestion of pcEXV-EndoL, into the EcoRI digested pCMV vector
(Invitrogen). The human betaglycan cDNA (19) cloned into the EcoRI
site of pSV7d vector, was kindly provided by Dr. Kohei Miyazono
(JFCR, Tokyo, Japan). The pCMV-Endo/Beta vector containing the
extracellular and transmembrane domains of endoglin and the cyto-
plasmic domain of betaglycan was obtained by replacing the 0.44-kb
MluI/EcoRI fragment of endoglin cDNA by the 0.3-kb MluI/EcoRI frag-
ment of a PCR product amplified from human betaglycan. Amplification
of human betaglycan cDNA (accession number S50051) was carried out
using the following primers: 59-CTCACACAGGGGAGACAGCAGG- 39
(position 3.044 to 3.065, including a MluI site) and 59-GAATTCTAGT-
GTGGTACAGAAGCCC-39 (position 3.395 to 3.371, including an EcoRI
site). The pSV7-Beta/Endo vector containing the extracellular domain
of betaglycan and the transmembrane and cytoplasmic domains of
endoglin was obtained in a triple in-frame reaction. The 2.6-kb EcoRI/
SspI fragment of betaglycan cDNA (19), the EcoRI/XbaI-digested
pSV7d expression vector, and the 0.6-kb SspI/XbaI fragment of the PCR
product number 3, amplified as described below, were ligated resulting
in the chimeric construct pSV7-Beta/Endo. The PCR product number 3
was obtained by a three-step amplification process. First, amplification
of L-endoglin cDNA (accession number J05481) was carried out using
the following primers: 59-GGCTATGCCATGCTGCTGGTGG-39 (oligo-
nucleotide EndoCyt2; position 1.919 to 1.940, including the stop codon),
and 59-GGTACATCTACTCTCACAC-39 (oligonucleotide EBC-1; posi-
tions 1.793 to 1.811 with a point mutation G 3 T at 1.806, containing
a highly homologous sequence with betaglycan), resulting in the 150-bp
PCR product number 1. The parallel amplification of betaglycan was
performed using the following primers: 59-GTGTGAGAGTAGATG-
TACC-39 (oligonucleotide EBC2; positions 3.032 to 3.050 with a point
mutation T 3 G at 3.042, containing a highly homologous sequence
with endoglin), and 59-CCATTATTGAGAATATTTGT-39 (oligonucleo-
tide SspI-OL; positions 2.576 to 2.597, including a SspI site), resulting
in the 476-base pair PCR product number 2. Next, annealed PCR
products numbers 1 and 2 were extended and amplified by Taq polym-
erase with oligonucleotides EndoCyt2 and SspI-OL, yielding the 0.6-kb
recombinant PCR product number 3. This fragment was cloned into
pCR2.TOPO vector (Invitrogen) and the 0.6-kb SspI/XbaI digestion
product was ligated, as described above. Plasmids pCMV5-TbR-II con-
taining the TGF-b receptor type II, and pCMV5-TbRI containing the
Alk-5 TGF-b receptor type I were generously provided by Dr. Joan
Massague´ (Howard Hughes Medical Institute, New York). The plasmid
pCMV5-TSR-I contains the Alk-1 TGF-b receptor type I (22). The EcoRI
fragment of S-endoglin (21) was subcloned into pCMV5 for resulting in
pCMV-EndoS. Plasmid p800 (kindly provided by Dr. Daniel B. Rifkin,
NYU Medical Center, NY) encodes the PAI-1 promoter (23) fused to the
luciferase reporter gene. The promoter activity of this construct has
been shown to be induced by TGF-b (24). The plasmid pSV2neo (CLON-
TECH) contains a neomycin resistance gene.
Cells and Stable Transfectants—The rat myoblast cell line L6E9 was
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% heat inactivated fetal calf serum, 2 mM L-glutamine, penicillin (100
units/ml), and gentamycin (25 mg/ml) in a 5% CO2 atmosphere at 37 °C.
Treatment of cells with recombinant human TGF-b1 (R&D Systems,
Abingdon, UK) was performed at a concentration of 500 pM for the times
indicated. L6E9 transfectants expressing betaglycan (20) were gener-
ously provided by Dr. Joan Massague´. Rat myoblast transfectants ex-
pressing human endoglin were generated by co-transfecting pcEXV-
EndoL or pCMV-Endo/Beta vectors and psV2neo at a 10:1 ratio. 10 mg
of plasmid DNA were mixed with 20 mg of Lipofectin (Life Technologies,
Inc.) in serum-free medium according to the protocol provided by the
manufacturer. Positive clones were selected in the presence of 400
mg/ml of the antibiotic G418. Parallel transfections with psV2neo alone
yielded endoglin-negative mock transfectants. Pooled clones were used
in biochemical and functional characterizations. No significant differ-
ences were observed between parental and mock transfectants in bio-
chemical and functional studies.
Confluent monolayers of adherent cells in 60-mm diameter dishes
were used in flow cytometry, biotinylation, and affinity labeling studies.
Adherent cells to be analyzed by flow cytometry, or adherent biotin-
labeled cells, were removed from culture dishes by incubation with
0.25% trypsin, 1 mM EDTA for 3 min at room temperature. Adherent
cells to be analyzed after TGF-b affinity labeling were removed from
culture dishes by incubation with 10 mM Tris-HCl, 150 mM NaCl, and 1
mM EDTA, pH 7.4, for 10 min at 4 °C, followed by gentle scraping with
a Teflon scraper.
Flow Cytometry—Cells (5 3 105) were incubated with the mouse mAb
8E11 (anti-endoglin) (25), the mouse mAb 44G4 (anti-fragment Y277-
G331 of human endoglin) (1, 26), or the rabbit polyclonal antibody 822
to the ectodomain of betaglycan (generous gift from Dr. Joan Massague´)
for 30 min at 4 °C. After two washes with PBS, fluorescein isothiocya-
nate-labeled F(ab9)2 rabbit anti-mouse or fluorescein isothiocyanate-
labeled pig anti-rabbit IgG (Dakopatts) were added and incubation
proceeded for an additional period of 30 min at 4 °C. Finally, cells were
washed twice with PBS and their fluorescence was estimated with an
EPICS-CS (Coulter Cientı´fica, Mo´stoles, Spain), using logarithmic
amplifiers.
Cell Surface Biotinylation—Cells were washed at 4 °C with Hepes
buffer (150 mM NaCl, 5 mM KOH, 1.3 mM CaCl2, 1.2 mM MgCl2, 10 mM
HEPES, pH 7.4) and allowed to equilibrate for 30 min at 4 °C in the
same buffer. Cells were washed again and fresh Hepes buffer contain-
ing 0.5 mg/ml sulfosuccinimidyl-6-(biotinamido)hexanoate (NHS-LC-
biotin, Pierce Chemical Co.) was added. After incubation at 4 °C for 2 h,
the reaction was stopped by washing twice with Hepes buffer. For
immunoprecipitation studies, cells were lysed in lysis buffer (10 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10 mg/ml
aprotinin, 10 mg/ml pepstatin, 50 mg/ml leupeptin, 1 mM benzamidine,
and 1 mM phenylmethylsulfonyl fluoride), for 40 min at 4 °C. The
lysates were centrifuged for 15 min at 12,000 3 g and the supernatants
were precleared for 4 h with protein G coupled to Sepharose (Pharmacia
Fine Chemicals, Uppsala, Sweden) at 4 °C. Specific immunoprecipita-
tions of the precleared lysates were carried out in the presence of either
the mouse mAb 44G4 (anti-fragment Y277-G331 of human endoglin) or
the rabbit polyclonal antibody 822 (anti-betaglycan ectodomain), using
protein G coupled to Sepharose. After overnight incubation at 4 °C,
immunoprecipitates were isolated by centrifugation and washed twice
with lysis buffer at 4 °C. Immune complexes were subjected to SDS-
PAGE on a 7.5% acrylamide gel under nonreducing conditions and then
electrotransferred to nitrocellulose. Filters were blocked with 5% pow-
der milk in PBS for 1 h and then incubated with 2 mg/ml streptavidin
conjugated to horseradish peroxidase (Pierce) for 2 h at room temper-
ature. Biotinylated endoglin or betaglycan were detected using an En-
hanced ChemiLuminescence system (Amersham Ibe´rica S.A., Madrid).
Proliferation Assays—Rat myoblasts were cultured in flat-bottomed
24-well plates (Costar, Cambridge, MA) at 4 3 104 cells/well in Dulbec-
co’s modified Eagle’s medium with 10% fetal calf serum in the absence
or presence of TGF-b1 for the times indicated, the last 6 h in the
presence of 1 mCi per well of [methyl-3H]thymidine (Amersham, United
Kingdom). Cells from triplicate samples were washed twice in PBS,
fixed in methanol for 30 min at 4 °C, and lysed in 0.1 N NaOH overnight.
Lysates were neutralized with HCl and [3H]thymidine incorporation
into DNA was measured in a liquid scintillation counter.
Receptor Affinity Labeling—Affinity labeling assays were basically
performed as described (27). For cross-linking experiments, cells were
incubated in Hepes buffer containing 0.1% bovine serum albumin with
50–250 pM 125I-TGF-b1 (specific activity 1, 200–2000 Ci/mmol; Amer-
sham Ibe´rica S.A., Madrid) for 4 h. Cells were washed and radiolabeled
TGF-b1 was cross-linked with 0.15 mM disuccinimidyl suberate (Pierce)
in Hepes buffer for 15 min at 4 °C. Cells were washed 4 times and
solubilized in lysis buffer. For each ligand concentration, cell associated
radioactivity was estimated in a g-counter (LKB, Bromma, Sweden).
The total extracts were subjected to SDS-PAGE analysis or to specific
immunoprecipitation. Immunoprecipitations were carried out with the
rabbit polyclonal antibody BN (anti-endoglin), generated by infection
with recombinant vaccinia virus expressing endoglin (28), or the rabbit
polyclonal antibody 822 (anti-betaglycan). Detection of the 125I-labeled
receptors was revealed by autoradiography or using a PhosphorImager
410A and ImageQuant software (Molecular Dynamics).
When required, cDNAs encoding human type I receptor (Alk-1 or
Alk-5), type II receptor, L-endoglin or S-endoglin in pCMV5 were tran-
siently transfected in different combinations into COS-7 cells. Basi-
cally, 20 mg of total plasmid DNA were mixed with 20 mg of Lipofectin
and incubated with COS cells following the protocol provided by Life
Technologies, Inc. After 48 h in culture, cells were affinity labeled with
125I-TGF-b and processed as described above.
PAI-1 Induction Assays—Experiments to determine PAI-1 synthesis
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were performed basically as described (29). For Western blot analysis,
subconfluent myoblasts were treated either in the absence or presence
of 100 pM TGF-b1 in Dulbecco’s modified Eagle’s medium containing
10% fetal calf serum overnight at 37 °C under 5% CO2 atmosphere.
Then, cells were lysed by washing on ice once with PBS, three times
with 10 mM Tris-HCl, pH 8, 0.5% deoxycholate, and 1 mM phenylmeth-
ylsulfonyl fluoride, twice with 2 mM Tris-HCl, pH 8, and once with PBS.
Next, 80 ml of electrophoresis sample buffer containing dithiothreitol
was added to each sample and dishes were scraped to recover all the
matrix proteins. Samples were denatured by boiling and aliquots con-
taining equal amounts of total protein were subjected to 10% SDS-
PAGE under reducing conditions. Proteins were electrotransferred to
nitrocellulose membranes (Millipore Corp., Bedford, MA). Filters were
blocked with PBS containing 5% milk powder for 1 h. Specific immu-
nodetection was carried out by incubation with rabbit IgG anti-rat
PAI-1 (Molecular Innovations Inc., Royal Oak, MI) overnight, followed
by peroxidase-conjugated goat anti-rabbit Ig at room temperature. The
presence of PAI-1, as a characteristic band of 45 kDa, was revealed
using a chemiluminescence assay (ECL detection kit, Amersham
Ibe´rica).
For immunoprecipitation analysis, subconfluent myoblasts were
treated either in the absence or presence of TGF-b1 as described above.
After treatment, cells were washed three times with methionine/cys-
teine-free medium (ICN Biomedicals, Barcelona) and preincubated in
this medium for 15 min, the medium was removed and fresh methio-
nine/cysteine-free medium containing 50 mCi/ml [35S]methionine/cys-
teine (Trans35S-Label, ICN Biomedicals) was added. Metabolic labeling
was carried out for 2 h either in the absence or presence of 500 pM
TGF-b1 at 37 °C. After labeling, supernatants were collected and sam-
ples containing equal amounts of protein bound radioactivity were
subjected to immunoprecipitation with a rabbit IgG anti-rat PAI-1
followed by SDS-PAGE analysis under reducing conditions. Detection of
the 35S-labeled PAI-1 was revealed by autoradiography.
PAI-1 promoter activity was assayed by transient transfections on
myoblasts using SuperFectTM (Qiagen). Briefly, 1 mg of the p800 plas-
mid, encoding the PAI-1 promoter, and 1 mg of CMVbgal were mixed
with 5 mg of SuperFectTM in Dulbecco’s modified Eagle’s medium. When
required, different combinations of expression vectors encoding betag-
lycan, L-endoglin, the chimera Endo/Beta, or the chimera Beta/Endo,
were also included. The mixture was incubated with the cells previously
seeded in a 24-well plate at 5 3 104 cells/well. The following day, cells
were incubated either in the absence or presence of 100 pM TGF-b1 for
an additional period of 24 h. Cells were lysed and the transduced
enzymatic activities were assayed. Internal normalization was done by
co-transfection of the test plasmid p800 with CMVbgal, a b-galactosid-
ase expression vector driven by the cytomegalovirus promoter. Lucifer-
ase activity was measured using a TD-20/20 Luminometer (Promega,
Madison, WI) and b-galactosidase activity was determined by meas-
uring the absorbance at 405 nm upon incubation with the substrate
ortho-nitrophenyl galactopyranoside (Sigma).
RESULTS
Endoglin Expression in Myoblasts Interferes with TGF-b Sig-
naling—To compare the role of endoglin with that of betagly-
can in the TGF-b signaling, we overexpressed by transfection
endoglin (L-endoglin isoform) and betaglycan in rat myoblasts
(Fig. 1). Both, endoglin and betaglycan were highly expressed
on the cell surface as determined by fluorescence flow cytom-
etry (Fig. 1A). Immunoprecipitation analysis (Fig. 1B) revealed
a 170-kDa band corresponding to the dimeric form of endoglin,
specifically recognized by anti-endoglin antibodies. Also, anti-
betaglycan antibodies specifically immunoprecipitated a broad
band of 190–300 kDa, corresponding to the mature betaglycan,
along with a minor band of approximately 120 kDa correspond-
ing to the putative betaglycan core. No specific reactivity could
be detected in mock transfectant cells either by flow cytometry
or immunoprecipitation analyses. Next, we analyzed the effect
of TGF-b in two functions known to be modulated by this factor
(Fig. 2). First, cellular proliferation of myoblasts is known to be
negatively affected by TGF-b1 (20). Endoglin overexpression
resulted in a deficient ligand response, at concentrations of
5–500 pM TGF-b1, with respect to mock transfectants (Fig. 2A).
By contrast, betaglycan expression led to an increased TGF-b
responsiveness, in agreement with a previous report (20). Next,
we analyzed the cellular PAI-1 synthesis, which is known to be
increased in the presence of TGF-b (12, 13). We then assayed
synthesis of PAI-1 by Western blot analysis of rat myoblasts
(Fig. 2, B and C). The levels of PAI-1 in response to TGF-b1
were found to be higher in betaglycan transfectants, or lower in
endoglin transfectants, than those of parental myoblasts. As a
control, immunoprecipitation analysis from metabolically la-
beled myoblasts revealed a characteristic 45-kDa band of
PAI-1, specifically recognized upon TGF-b treatment (Fig. 2B).
FIG. 1. Characterization of stable
myoblast transfectants expressing
endoglin or betaglycan. A, analysis by
cytofluorometry of endoglin and betagly-
can present at the cell surface. Myoblasts
were stained for indirect immunofluores-
cence with anti-endoglin or anti-betagly-
can antibodies, as indicated. A control
staining of mock transfectants is also
shown. B, immunoprecipitation analysis.
Myoblasts were surface labeled with bio-
tin, lysed, and immunoprecipitated with
anti-endoglin or anti-betaglycan antibod-
ies, as indicated. Samples were electro-
phoresed on a 7.5% acrylamide gel under
nonreducing conditions, transferred to ni-
trocellulose and biotinylated polypeptides
detected using a chemiluminescence as-
say. Bands corresponding to endoglin, be-
taglycan, or the putative betaglycan core
(C) are indicated. Minor bands of approx-
imately 100 kDa are likely unspecific as
they could be detected with variable in-
tensity in mock transfectants.
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Furthermore, we assayed the PAI-1 promoter activity which
can be induced by TGF-b (24). As expected, mock transfectants
showed an increased transcriptional activity of PAI-1, whereas
betaglycan transfectants displayed an even higher response
(Fig. 2D). By contrast, no induction of the PAI-1 promoter
activity could be detected in endoglin transfectants. Taken
together, these results demonstrate that, at variance with be-
taglycan, expression of endoglin in myoblast cells interferes
with signaling responses to TGF-b1.
The Effect of Endoglin in TGF-b Responses Resides in the
Extracellular Domain—Given the distinct effect of endoglin
and betaglycan with respect to the cellular TGF-b responses,
we engineered the chimeric constructs Endo/Beta and Beta/
Endo to determine the specific endoglin domain involved (Fig.
3A). The Endo/Beta construct encodes a chimeric protein with
the extracellular and transmembrane domains of endoglin
fused to the cytoplasmic region of betaglycan; the Beta/Endo
construct encodes a chimeric protein with the extracellular and
transmembrane domains of betaglycan fused to the cytoplas-
mic region of endoglin. These constructs were transiently
transfected into parental myoblasts and the TGF-b inducibility
of the PAI-1 promoter was analyzed (Fig. 3B). As expected,
parental cells showed an increased PAI-1 activity in the pres-
ence of TGF-b. Cells transfected with betaglycan or Beta/Endo
chimera showed an increased PAI-1 response as compared with
parental myoblasts. By contrast, the PAI-1 promoter activity of
cells transfected with endoglin or Endo/Beta chimera did not
respond to TGF-b. As a control, cells transiently transfected
with all these constructs demonstrated the expression of the
corresponding recombinant proteins at the cell surface (data
FIG. 2. Functional characterization of stable myoblast transfectants. A, effect of endoglin or betaglycan expression on the TGF-b1-
induced inhibition of proliferation. Myoblast transfectants were incubated with increasing concentrations of TGF-b1 (5–500 pM) and the
proliferation capacity of the cells was measured by [3H]thymidine incorporation. The pattern of TGF-b1 inhibition of proliferation was the same
in parental and mock transfected myoblasts. The mean of five different experiments performed in triplicate samples is shown. Standard deviations
are indicated. B, effect of endoglin or betaglycan expression on the TGF-b1-induced PAI-1 synthesis. Myoblast transfectants (1Betaglycan and
1Endoglin) and parental cells were incubated either in the absence or presence of TGF-b1 and extracellular matrix proteins solubilized as
described under “Experimental Procedures.” Samples containing equal amounts of total protein were subjected to SDS-PAGE under reducing
conditions and analyzed by Western blot (WB) using a rabbit IgG anti-rat PAI-1 (a-PAI-1) or a non-immune rabbit IgG (NI-IgG). For immuno-
precipitation (IP) studies parental myoblasts were metabolically labeled with [35S]methionine/cysteine for 4 h either in the absence or presence of
TGF-b1 as indicated. Radiolabeled culture supernatants were collected and samples containing equal amounts of protein bound radioactivity were
immunoprecipitated with rabbit IgG anti-rat PAI-1 or non-immune rabbit IgG. Immunoprecipitates were analyzed by SDS-PAGE under reducing
conditions followed by autoradiography. The TGF-b1 induction of PAI-1 was similar in parental and mock transfected myoblasts. The characteristic
45-kDa band of PAI-1 is indicated by arrowheads. C, the PAI-1 bands of the Western blot analysis (panel B) were quantitated by densitometry using
a PhosphorImager 410 and ImageQuant software. D, TGF-b induction of PAI-1 promoter activity in myoblast transfectants. Myoblast transfectants
were transiently transduced with the p800 construct containing the PAI-1 promoter fused to the luciferase gene. TGF-b1 was added 24 h after
transfection to half of the transfected cells and luciferase activity was determined 48 h after transfection. The TGF-b1 inducibility of the PAI-1
promoter was similar in parental and mock transfected myoblasts. For comparative purposes, values of untreated cells were arbitrarily set at 100.
The mean of three different experiments is shown.
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not shown). These data suggest the involvement of the extra-
cellular domains of endoglin or betaglycan in their capacity to
modulate TGF-b responses. This was confirmed by prolifera-
tion studies using stable myoblast transfectants expressing the
Endo/Beta chimera (Fig. 4). The mAb 44G4 to the extracellular
domain of endoglin (26) demonstrated by flow cytometry the
cell surface expression of the chimera in myoblasts stably
transfected with the pcEXV-Endo/Beta construct (Fig. 4A). The
same mAb was used in immunoprecipitation analysis (Fig. 4B),
revealing a 170-kDa band corresponding to the endoglin/beta-
glycan chimeric protein. As expected, the polyclonal antibody
822 to the extracellular domain of betaglycan did not recognize
the chimeric protein. Then, we analyzed the effect of TGF-b in
the cellular proliferation of the myoblasts expressing the chi-
mera. As shown in Fig. 2, endoglin overexpression was associ-
ated with a deficient response to TGF-b1 with respect of mock
transfectants. Fig. 4C reveals that expression of the chimeric
protein resulted in a similar unresponsiveness to TGF-b1,
whereas betaglycan transfectants showed an increased respon-
siveness. Taken together, these results suggest that the extra-
cellular domain of endoglin is responsible for its modulatory
role in TGF-b cellular responses.
Binding of TGF-b to Signaling Receptors in Myoblast Trans-
fectants—Given the distinct modulatory effect of endoglin and
betaglycan on TGF-b signaling, it was of interest to study
ligand binding to the myoblast transfectants. TGF-b1 binding
to cell transfectants was analyzed by affinity labeling followed
by cross-linking at different concentrations of ligand. Fig. 5A
shows that specific binding to mock, endoglin, and betaglycan
transfectants was increased in a dose-dependent manner.
Binding to betaglycan expressing cells was clearly increased
(about 3.5-fold at 100–200 pM) with respect to mock cells,
whereas binding to endoglin transfectants was only slightly
incremented (about 1.7-fold at 100–200 pM). The species bind-
ing TGF-b1 were analyzed by SDS-PAGE fractionation of total
lysates (Fig. 5B). Two distinct polypeptides of approximately 66
and 90 kDa corresponding to the putative TGF-b receptors type
I and II, respectively, could be detected in mock transfectants
at 200 pM ligand. The labeling of these two receptors was
enhanced in endoglin transfectants, whereas betaglycan ex-
pressing myoblasts displayed only increased ligand binding to
putative R-II. However, the presence of high molecular mass
receptors (.130 kDa) were more abundant in betaglycan trans-
fectants than in mock or endoglin transfectants. These high
molecular weight receptors likely correspond to betaglycan-
ligand complexes, as indicated by immunoprecipitation exper-
iments with specific antibodies (Fig. 5C). Thus, a band of mo-
lecular masss .200 kDa corresponding to mature betaglycan
was immunoprecipitated from betaglycan transfectants, but
not from parental myoblasts. In addition, the putative beta-
glycan core (17, 18) could be detected as a band of approxi-
mately 120 kDa. Binding of TGF-b1 to endoglin could also be
demonstrated by immunoprecipitation with anti-endoglin an-
tibodies. Specific bands of 200 kDa (nonreducing conditions)
and 100 kDa (reducing conditions) corresponding to the dimeric
or monomeric forms of endoglin were specifically immunopre-
cipitated from endoglin transfectants, but not from parental
myoblasts. These experiments also revealed the association of
endoglin and betaglycan with the putative R-I and R-II. This is
in agreement with previous reports demonstrating the forma-
FIG. 3. Effect of Endo/Beta and Be-
ta/Endo chimera expression on the
TGF-b inducibility of the PAI-1 pro-
moter. A, schematic representation of the
protein chimeras encoded by Endo/Beta
and Beta/Endo constructs. The extracel-
lular (EC), transmembrane (TM), and
cytoplasmic (CY) domains of the proteins
are indicated. The cDNA-encoded poly-
peptide of human betaglycan is 849 amino
acids long, whereas the one encoded by
human L-endoglin contains 658 residues.
The proteins are represented approxi-
mately to scale. Sequences corresponding
to betaglycan or endoglin are depicted by
hatched or open boxes, respectively. B,
TGF-b inducibility of the PAI-1 promoter.
Parental myoblasts were transiently co-
transfected with the p800 construct and
expression vectors encoding betaglycan,
L-endoglin, the chimera Endo/Beta or the
chimera Beta/Endo, as indicated. TGF-b1
was added 24 h after transfection to half
of the transfected cells and luciferase ac-
tivity was determined 48 h after transfec-
tion. For comparative purposes, values of
untreated cells were arbitrarily set at
100. The mean of four different experi-
ments performed in duplicates is shown.
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tion of heteromeric complexes between endoglin or betaglycan
with the signaling receptors (7, 20, 30). In several immunopre-
cipitation experiments, we found that the contribution of the
signaling receptors relative to the endoglin signal was higher
than the equivalent ratio in betaglycan immunoprecipitates.
This is especially evident in the endoglin immunoprecipitate at
20 pM TGF-b1 under reducing conditions of Fig. 5C where the
labeling of R-I, but not that of endoglin, could be detected. This
suggests the existence of endoglin free of ligand associated with
signaling receptors loaded with TGF-b. Taken together, these
results indicate that endoglin differs from betaglycan in the
modulation of TGF-b binding to the cell.
Requirement for Signaling Receptors in the Binding of
TGF-b1 to Endoglin—Given the positive influence of endoglin
on TGF-b binding to the signaling receptors, we wondered
whether the signaling receptors could influence TGF-b binding
to endoglin. Initially, we tried unsuccesfully to generate stable
myoblast transfectants expressing different combinations of
receptors type I, type II, and endoglin. Then, we addressed this
issue by transient transfection in COS cells, as this is a model
system commonly used to evaluate ligand binding of trans-
duced receptors of the TGF-b family. Plasmids encoding the
L-endoglin isoform (21) and R-II were transfected in different
combinations. The transduced cells were radiolabeled with
TGF-b1, followed by cross-linking and analysis of the lysates by
SDS-PAGE (Fig. 6A). Cells transfected with R-II showed an
strong 90-kDa band, in agreement with previous reports dem-
onstrating that R-II is constitutively active in binding the li-
gand (22). Under nonreducing conditions, cells co-transfected
with L-endoglin and R-II showed a 200-kDa band likely corre-
sponding to endoglin as it migrated as a 100-kDa band (over-
lapping with R-II) under reducing conditions. The fact that
binding of TGF-b to endoglin is only revealed when co-ex-
pressed with R-II, suggests that R-II potentiates binding to
endoglin. Similar experiments using a plasmid encoding R-I
instead of R-II, did not reveal increased ligand binding to
endoglin (data not shown). Specific immunoprecipitation anal-
ysis confirmed the increased ligand binding to both endoglin
isoforms in the presence of R-II (Fig. 6B). By contrast, the R-I
(Alk-1 or Alk-5) failed to induce ligand binding to endoglin. As
a control, expression levels of endoglin were found to be similar
in the different co-transfection protocols, as demonstrated by
biotin labeling. Overexposure of immunoprecipitates from COS
cells only transfected with endoglin vector revealed a specific
band of radiolabeled TGF-b1-endoglin complex (data not
shown), in agreement with a previous report (6). These data
demonstrate the important role of the type II receptor in TGF-b
binding to endoglin.
DISCUSSION
The cellular TGF-b receptor system is formed by several
membrane receptors including receptors I and II, betaglycan,
and endoglin. The core of this receptor system seems to be
located in the heteromeric association between receptor I and
receptor II, whose signals, mediated by their cytoplasmic do-
mains with Ser/Thr kinase activities, are crucial in the TGF-b
dependent effector functions. Here, we have used for the first
time the same cellular system to analyze the role of endoglin
and its homologue betaglycan in the TGF-b-dependent re-
sponses. Endoglin expression was found to inhibit the TGF-b1-
dependent responses of cellular proliferation and PAI-1 expres-
sion, as opposed to an increased TGF-b1 responsiveness
induced by betaglycan expression. These results agree with
previous reports analyzing the role of betaglycan (20) or endog-
lin (9) in different cellular lineages. The negative role of endog-
lin in TGF-b signaling seems to be located in the extracellular
domain of endoglin as evidenced by the functional analysis of
two chimeric proteins containing different combinations of en-
doglin and betaglycan domains. This functional mapping is
FIG. 4. Characterization of transfectant myoblasts expressing
a chimeric endoglin/betaglycan. The rat myoblast cell line L6E9 was
stably transfected with the pCMV-Endo/Beta vector encoding the ex-
tracellular and transmembrane domains of endoglin fused to the cyto-
plasmic region of betaglycan, and the expression and function of the
chimeric protein was analyzed. A, analysis by cytofluorometry of the
chimeric protein present at the cell surface. Myoblast transfectants
were stained for indirect immunofluorescence with the mAb 44G4 to the
extracellular domain of endoglin. A, control staining of mock transfec-
tants is also shown. B, immunoprecipitation analysis. Myoblast trans-
fectants were surface labeled with biotin, lysed, and immunoprecipi-
tated with antibodies to the ectodomain of either endoglin (mAb 44G4)
or betaglycan (polyclonal antibody 822). Samples were electrophoresed
on a 7.5% acrylamide gel under nonreducing conditions, transferred to
nitrocellulose, and the biotinylated protein detected using a chemilu-
minescence assay. C, TGF-b1-induced inhibition of proliferation. Stable
myoblast transfectants expressing endoglin, betaglycan, or the Endo/
Beta chimera were incubated with 500 pM TGF-b1 and the proliferation
capacity of the cells was measured by [3H]thymidine incorporation.
Mock transfectants (Control) and parental myoblasts displayed a sim-
ilar TGF-b1 inhibition of proliferation. The mean of four different
experiments performed in triplicate samples is shown.
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compatible with the fact that the S-endoglin isoform, which has
a cytoplasmic domain different from that of L-endoglin isoform
used throughout this study, also displays a negative effect on
TGF-b1 responses (9). Furthermore, the high homology dis-
played by the cytoplasmic domains of betaglycan and the L-
endoglin isoform (16, 19), favors an active role of their extra-
cellular domains as responsible for the distinct TGF-b effector
functions.
The opposite functional behavior of endoglin and betaglycan
increases a list of differences between these two receptors,
which include the cellular distribution, or the specificity for
TGF-b isoforms. Another major difference has been found in
FIG. 5. Binding of TGF-b1 to specific receptors on myoblast transfectants. Cells were affinity labeled by incubation at 4 °C with 25–200
pM 125I-TGF-b1 and washed as described under “Experimental Procedures.” Radiolabeled TGF-b1 was cross-linked to the specific receptors with
disuccinimidyl suberate, cells were lysed and cell associated radioactivity was estimated in a g-counter (panel A). Total extracts were subjected to
SDS-PAGE analysis under nonreducing conditions (panel B) or to specific immunoprecipitation (panel C). Immunoprecipitations were carried out
with the rabbit polyclonal antibody BN (anti-endoglin) or the rabbit polyclonal antibody 822 (anti-betaglycan) followed by SDS-PAGE under
reducing (R) or nonreducing (NR) conditions. Detection of the 125I-labeled receptors in the gels was revealed by autoradiography or using a
PhosphorImager. High molecular weight bands corresponding to oligomers, endoglin, or betaglycan, and bands corresponding to the putative
betaglycan core and receptors type I or II are indicated. L, 1betaglycan; M, 1endoglin; D, mock.
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the ability to bind TGF-b1 of these receptors. Betaglycan,
readily binds TGF-b (17), as confirmed here by its extensive
labeling in cross-linking experiments of myoblast transfectants
(Fig. 5). This contrasts with the weak labeling of endoglin, even
though the levels of expression of endoglin appeared to be
higher than those of betaglycan (Fig. 1A). Likewise, in endo-
thelial cells, where endoglin expression is high (up to 106 mol-
ecules per cell), only a small number of endoglin molecules bind
TGF-b1 (6). Several explanations could account for this low
binding. First, there is a physiological ligand different from
TGF-b. In support of this hypothesis is the fact that mutations
in Alk-1, a type I receptor with unknown ligand specificity, lead
to a similar phenotype as in HHT1 patients (31). Second, en-
doglin requires the expression of additional molecules to bind
TGF-b. This agrees with: (a) the existence of endoglin free of
ligand associated with signaling receptors loaded with TGF-b
(Fig. 5C); and (b) the requirement of R-II expression for ligand
binding to endoglin (Fig. 6). This is a remarkable difference
with betaglycan, which binds TGF-b independently from the
signaling receptors as demonstrated by the ligand binding of its
soluble form (17, 32). It also remains possible that endoglin
binds TGF-b1 only when associated with signaling receptor II,
but its major function is not to be a component of the TGF-b
receptor system. All these alternatives remain to be explored.
Overall, the cooperative effects observed in the TGF-b bind-
ing to the endoglin containing receptor complex resemble those
observed with different combinations of receptors I, II, and III
(20, 30, 33, 34). Despite their distinct functional effects, expres-
sion of endoglin or betaglycan was associated with a potentia-
tion of ligand binding to the signaling receptors. It is unclear
how the loss of TGF-b signaling in endoglin transfectants can
harmonize with the enhanced receptor binding. However, it is
worth noting that the binding assays are performed at 4 °C, far
from the in vivo situation, and also that these assays do not
unveil the final destination of the ligand bound. It has been
proposed that betaglycan presents TGF-b2 to the signaling
receptors, which in turn, increase the signaling (20). In princi-
ple, this model cannot be applied to endoglin. Rather, our data
agree with the behavior of betaglycan transfectants which
show a normal TGF-b1 response, but an increased ligand bind-
ing to the signaling receptors (20), indicating that both ligand
response and binding can be uncoupled under certain condi-
tions. On the other hand, the requirement of the R-II for the
TGF-b binding to endoglin appears to be compatible with the
inhibition of the TGF-b responses found in endoglin transfec-
tants. According to the hypothetical model depicted in Fig. 7,
the receptor II-induced ligand binding to endoglin might be
interpreted as a deflection of the ligand from the signaling core.
Similarly to endoglin, R-I has been reported to require the
presence of R-II for ligand binding, although in this case the
increased binding is associated with an increased TGF-b re-
sponse (35). By contrast, increased binding to endoglin, a non-
signaling receptor, could lead to a sequestering of the ligand
associated with a loss of cellular responses to TGF-b. Whether
endoglin is a mere reservoir or scavenger receptor, or whether
it is also actively involved in the modulation of the downstream
signaling, remains to be determined.
FIG. 6. Binding of TGF-b1 to COS cells expressing endoglin,
and receptor types I and II. COS cells were transiently transfected
with the pCMV5 expression vector containing cDNAs encoding R-I
(Alk-1 or Alk-5), R-II, and endoglin (S-endoglin or L-endoglin), as indi-
cated. After 2 days in culture, cells were affinity labeled with 125I-
TGF-b1 and cross-linked with disuccinimidyl suberate. A, total lysates
were analyzed on a 6% acrylamide gel under either reducing or nonre-
ducing conditions, followed by detection of the radiolabeled receptors
with a PhosphorImager. The positions of endoglin, R-I, and R-II are
indicated. B, immunoprecipitation analysis. Total lysates were sub-
jected to immunoprecipitation with anti-endoglin antibodies, followed
by SDS-PAGE analysis under nonreducing conditions. Radioactive
bands were detected with a PhosphorImager (upper panel). As a control
for endoglin expression, cells were biotinylated on their surface, lysed,
and immunoprecipitated with anti-endoglin antibodies. Samples were
run on SDS-PAGE under nonreducing conditions and electrotrans-
ferred to nitrocellulose membranes. Biotinylated proteins were detected
with streptavidin conjugated to horseradish peroxidase using a chemi-
luminescence assay (lower panel). Only the area of the gels correspond-
ing to labeled endoglin is shown. The positions of L-endoglin (L) and
S-endoglin (S) are indicated.
FIG. 7. Schematic representation of a possible model of TGF-b
binding and signaling. The type II receptor (R-II) is required for
binding of TGF-b to the type I receptor (R-I) leading to an increased
signal transduction. By contrast, the type II receptor allows binding of
TGF-b to endoglin, which is associated with a loss of signal transduc-
tion. The constitutive phosphorylation (P) of endoglin is indicated. For
further discussion and references, see the text.
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